Severe hypo-α-lipoproteinemia during treatment with rosiglitazone

Diabetes Care

Volumn 27, Issue 11, 2004, Pages 2577-2580

  Sarker, Anita ^a   Semple, Robert K ^a   Dinneen, Sean F ^a   O'Rahilly, Stephen ^a   Martin, Steven C ^a,b  

^a ADDENBROOKE S HOSPITAL   (United Kingdom)

^b WEST SUFFOLK HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN A2; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; PIOGLITAZONE; ROSIGLITAZONE;

ADULT; ARTICLE; CARDIOVASCULAR RISK; CASE REPORT; CHOLESTEROL BLOOD LEVEL; DISEASE SEVERITY; DRUG EFFECT; DRUG WITHDRAWAL; DYSLIPIDEMIA; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPOALPHALIPOPROTEINEMIA; HYPOLIPOPROTEINEMIA; INSULIN RESISTANCE; INSULIN SENSITIVITY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; RISK BENEFIT ANALYSIS; SIDE EFFECT;

APOLIPOPROTEIN A-I; CHOLESTEROL, HDL; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; THIAZOLIDINEDIONES;

EID: 7444253876     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.27.11.2577     Document Type: Article

References (11)

1. Goldstein BJ: Differentiating members of the thiazolidinedione class: a focus on efficacy. Diabetes Metab Res Rev 18 (Suppl. 2):S16-S22, 2002
2. Berger J, Moller DE: The mechanisms of action of PPARs. Annu Rev Med 53:409-435, 2002
3. Beghin L, Capps N, Duhal N, Davies J, Staels B, Luc G. Metabolism of apolipoproteins AI and AII in a patient with paradoxical reduction in high-density lipoprotein due to ciprofibrate. Ann Clin Biochem 36:523-525, 1999
4. Sacks FM: The role of high-density lipoprotein (HDL) cholesterol in the prevention and treatment of coronary heart disease: expert group recommendations. Am J Cardiol 90:139-143, 2002
5. Phillips LS, Grunberger G, Miller E, Patwardhan R, Rappaport EB, Salzman A: Once- and twice-daily dosing with rosiglitazone improves glycemic control in patients with type 2 diabetes. Diabetes Care 24:308-315, 2001
6. Wolffenbuttel BH, Gomis R, Squatrito S, Jones NP, Patwardhan RN: Addition of low-dose rosiglitazone to sulphonylurea therapy improves glycaemic control in type 2 diabetic patients. Diabet Med 17: 40-47, 2000
7. Fonseca V, Rosenstock J, Patwardhan R, Salzman A: Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial. JAMA 283: 1695-1702, 2000
8. Rashid S, Watanabe T, Sakaue T, Lewis GF: Mechanisms of HDL lowering in insulin resistant, hypertriglyceridemic states: the combined effect of HDL triglyceride enrichment and elevated hepatic lipase activity. Clin Biochem 36:421-429, 2003
9. Vu-Dac N, Chopin-Delannoy S, Gervois P, Bonnelye E, Martin G, Fruchart JC, Laudet V, Staels B: The nuclear receptors peroxisome proliferator-activated receptor alpha and Rev-erbalpha mediate the species-specific regulation of apolipoprotein A-I expression by fibrates. J Biol Chem 273:25713-25720, 1998
10. Boelsterli UA, Bedoucha M: Toxicological consequences of altered peroxisome proliferator-activated receptor gamma (PPARgamma) expression in the liver: insights from models of obesity and type 2 diabetes. Biochem Pharmacol 63:1-10, 2002
11. Ebcioglu Z, Morgan J, Carey C, Capuzzi D: Paradoxical lowering of high-density lipoprotein cholesterol level in 2 patients receiving fenofibrate and a thiazolidinedione (Letter). Ann Intern Med 139:W80, 2003